Medical skilled calls for transition from favipiravir to simpler molnupiravir

A leading health skilled says Thailand ought to part out the usage of favipiravir, saying molnupiravir is a more effective Covid-19 treatment. Dr Opass Putcharoen, from the Thai Red Cross Emerging Infectious Diseases Clinical Centre, says this shall be important as the nation strikes to declaring Covid-19 endemic. He added that the cost of molnupiravir produced in India is someplace between 600 and 700 baht per treatment course, compared to 50,000 baht for the molnupiravir version produced by Merck.
According to a Bangkok Post report, the Public Health Ministry has beforehand said that a course of favipiravir costs around 1,000 baht, whereas a molnupiravir treatment course prices 10,000 baht. Earlier this week, Cabinet gave the go-ahead to ditch a procurement plan for 50,000 doses of molnupiravir, in favour of 17 million favipiravir tablets and 5,166 vials of the antiviral medicine, remdesivir.
Opass points out that while favipiravir has been the main therapy of selection in Thailand, there is not any clear knowledge that proves its efficacy. By distinction, a latest research shows that molnupiravir is 30% efficient at stopping severe sickness in Covid-19 sufferers. The medic is calling on the federal government to import molnupiravir from India and ensure all hospitals have sufficient supplies, so it can be administered promptly to those that need it.
He goes on to say that certain classes of Covid-19 patients are nonetheless vulnerable to extreme illness, even if they’re fully vaccinated. These embody people on immunosuppressive medicine, who want access to effective treatment. Become an insider adds that whereas new infections are expected to drop 2 – 3 weeks after the Songkran holiday, the virus still must be closely monitored..

Leave a Comment